You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

OCTREOSCAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Octreoscan patents expire, and what generic alternatives are available?

Octreoscan is a drug marketed by Curium and is included in one NDA.

The generic ingredient in OCTREOSCAN is indium in-111 pentetreotide kit. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetreotide kit profile page.

Summary for OCTREOSCAN
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 20
Patent Applications: 79
What excipients (inactive ingredients) are in OCTREOSCAN?OCTREOSCAN excipients list
DailyMed Link:OCTREOSCAN at DailyMed
Drug patent expirations by year for OCTREOSCAN
Recent Clinical Trials for OCTREOSCAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AHS Cancer Control AlbertaPhase 1/Phase 2
Alexander McEwanPhase 1/Phase 2
AC Camargo Cancer CenterPhase 2

See all OCTREOSCAN clinical trials

US Patents and Regulatory Information for OCTREOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OCTREOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ⤷  Try a Trial ⤷  Try a Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ⤷  Try a Trial ⤷  Try a Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ⤷  Try a Trial ⤷  Try a Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for OCTREOSCAN

See the table below for patents covering OCTREOSCAN around the world.

Country Patent Number Title Estimated Expiration
Denmark 175338 ⤷  Try a Trial
Germany 3991505 Somatostatinpeptide, deren Analoga oder Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen ⤷  Try a Trial
Greece 890100803 ⤷  Try a Trial
Germany 69231324 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.